Investigating the role of type II arginase in tuberculosis
Official title: Type II arginase and tuberculosis pathogenesis
Funded at Rutgers Biomedical and Health Sciences · NIH-10990543 · Data updated 2026-11-12
This study is looking at how a specific enzyme called type II arginase (ARG2) influences the immune system's response to tuberculosis (TB), with the hope of finding better ways to treat the disease.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project start | November 20, 2023 |
| Project end | October 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $228,435 |
| NIH project number | 5R21AI180662-02 |
| Project ID | NIH-10990543 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with tuberculosis, particularly those who may be at risk for multi-drug-resistant strains.
✕Less likely to help
Patients with other infectious diseases unrelated to tuberculosis may not receive any benefit from this research.
What this research studies
This research focuses on understanding how type II arginase (ARG2) affects the immune response to tuberculosis (TB) caused by Mycobacterium tuberculosis. By studying animal models, the researchers aim to uncover the metabolic changes in immune cells during TB infection and how these changes can be harnessed to improve treatment outcomes. The study involves analyzing the dynamics of macrophage responses and the role of ARG2 in regulating inflammation and metabolism. The ultimate goal is to develop new therapies that can enhance the effectiveness of existing TB treatments.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve treatment outcomes for patients with tuberculosis.
How similar studies have gone: Previous research has shown promise in targeting metabolic pathways in immune responses, suggesting that this approach could yield significant advancements in TB treatment.
Where this research is happening
-
Rutgers Biomedical and Health Sciences
Newark, United States Active
Researchers
- Principal investigator: Shi, Lanbo — Rutgers Biomedical and Health Sciences
- Study coordinator: Shi, Lanbo
Related research
Other NIH-funded projects on the same topics.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
Pulmonary rehabilitation to reduce breathing problems after tuberculosis
A program of guided exercise and breathing training to help adults who have recovered from TB breathe better and feel healthier.
-
Pulmonary rehab to reduce breathing troubles after TB
A program of pulmonary rehabilitation is being studied to help adults who have completed TB treatment avoid ongoing lung problems and improve daily breathing.
-
Air pollution and tuberculosis spread in Kampala, Uganda
This project looks at whether dirty air from PM2.5 particles makes tuberculosis more likely to spread within urban slum households in Kampala, Uganda.
-
Air pollution and TB spread in Ugandan urban slums
This project explores whether exposure to air pollution makes tuberculosis more likely to spread within households in a crowded Ugandan slum.
-
Air pollution and TB transmission in Kampala’s urban slums
This project looks at whether air pollution from PM2.5 makes tuberculosis spread more easily from infected people to their neighbors in urban slums of Kampala, Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.